Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900
Debt
Debt-to-Equity Ratio0.69
Current Ratio0.71
Quick Ratio0.59
Price-To-Earnings
Trailing P/E Ratio11.90
Forward P/E Ratio10.60
P/E Growth1.21
Sales & Book Value
Annual Sales$100.06 billion
Price / Sales0.54
Cash Flow$10.5312 per share
Price / Cash9.13
Book Value$32.00 per share
Price / Book3.00
Profitability
EPS (Most Recent Fiscal Year)$7.10
Net Income$4.52 billion
Net Margins4.65%
Return on Equity25.49%
Return on Assets8.58%
Miscellaneous
Employees26,600
Outstanding Shares562,120,000
Market Cap$53.83 billion
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, December 20th 2017, which authorizes the company to buyback 45,000,000 shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding Co (NASDAQ:ESRX) released its quarterly earnings results on Wednesday, August, 1st. The company reported $2.22 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.20 by $0.02. The company had revenue of $25.64 billion for the quarter, compared to the consensus estimate of $25.43 billion. Express Scripts had a return on equity of 25.49% and a net margin of 4.65%. Express Scripts's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.73 EPS. View Express Scripts' Earnings History.
When is Express Scripts' next earnings date?
What guidance has Express Scripts issued on next quarter's earnings?
Express Scripts issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of $9.00-9.14 for the period, compared to the Thomson Reuters consensus estimate of $9.05. The company issued revenue guidance of $99-102 billion, compared to the consensus revenue estimate of $100.99 billion.
What price target have analysts set for ESRX?
17 analysts have issued 1 year price objectives for Express Scripts' shares. Their predictions range from $75.00 to $101.00. On average, they anticipate Express Scripts' share price to reach $86.5385 in the next year. This suggests that the stock has a possible downside of 10.0%. View Analyst Price Targets for Express Scripts.
What is the consensus analysts' recommendation for Express Scripts?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 1 sell rating, 12 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.
What are Wall Street analysts saying about Express Scripts stock?
Here are some recent quotes from research analysts about Express Scripts stock:
- 1. According to Zacks Investment Research, "Express Scripts currently faces persistent drug pricing issue, which is anticipated to affect the stock. A lackluster guidance for 2018 also raises concern. Moreover, the company faces stiff competition in niche space. Express Scripts announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with the company anymore. Furthermore, the company is getting acquired by Cigna Corporation. However, the company has been benefitting from a rise in patient claims and strong customer retention. Express Scripts' PBM segment coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. Furthermore, recent collaborations also deserve mention. Notably, management expects cumulative savings of nearly $1.2 billion by 2021. Express Scripts outperformed its industry in past year." (7/23/2018)
- 2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)
Are investors shorting Express Scripts?
Express Scripts saw a decrease in short interest in the month of September. As of September 14th, there was short interest totalling 13,650,076 shares, a decrease of 8.7% from the August 31st total of 14,943,257 shares. Based on an average daily trading volume, of 4,210,536 shares, the days-to-cover ratio is currently 3.2 days. Currently, 2.4% of the company's shares are short sold. View Express Scripts' Current Options Chain.
Who are some of Express Scripts' key competitors?
Who are Express Scripts' key executives?
Express Scripts' management team includes the folowing people:
- Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
- Mr. James M. Havel, Exec. VP & CFO (Age 63)
- Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
- Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
- Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by many different of institutional and retail investors. Top institutional investors include Swedbank (0.23%), Bank of Montreal Can (0.13%), Aperio Group LLC (0.10%), State of New Jersey Common Pension Fund D (0.09%), Hexavest Inc. (0.09%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Express Scripts stock include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which major investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, DNB Asset Management AS, Bowling Portfolio Management LLC, Chesley Taft & Associates LLC, Swedbank, Hexavest Inc., Empirical Finance LLC and Addenda Capital Inc.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin and Phyllis S Anderson. View Insider Buying and Selling for Express Scripts.
Which major investors are buying Express Scripts stock?
ESRX stock was purchased by a variety of institutional investors in the last quarter, including Seven Eight Capital LP, Havens Advisors LLC, Contravisory Investment Management Inc., Bank of Montreal Can, Kassirer Asset Management Corp, Nisa Investment Advisors LLC, Aperio Group LLC and First Citizens Bank & Trust Co.. View Insider Buying and Selling for Express Scripts.
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $96.15.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $53.83 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.
What is Express Scripts' official website?
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
